Medica Scientia Innovation Research S.L.

Medica Scientia Innovation Research S.L. concentrates much of its clinical research activity on advanced breast cancer, with particular attention to triple-negative breast cancer, hormone receptor-positive disease, HER2-positive disease, and HER2-low and HER2-ultralow subtypes. Its studies also include early-stage breast cancer, metastatic breast cancer, and biologically defined groups such as ESR1-mutated, PIK3CA-mutated, and PTEN-altered tumors.

• Triple-negative breast cancer
• HER2-positive and HER2-low breast cancer
• Hormone receptor-positive breast cancer
• Early breast cancer
• Metastatic breast cancer

The portfolio also includes research in metaplastic breast cancer, aggressive disease settings, and breast tumors with distinct molecular features that guide treatment selection.